Treovir announces today that it has executed an Asset Acquisition Agreement with Aettis, Inc. to acquire 100% of the assets relating to G207, a clinical stage product currently in clinical trials to treat pediatric brain tumors. The assignment includes all regulatory documentation including IND 7393 with the US FDA, and the proprietary cell bank and viral bank materials necessary for the production and development of G207. Other terms of the agreement remain confidential.